- Overview Tuberculosis and Vitamin D
- Pulmonary Tuberculosis 2X more likely if poor Vitamin D Receptor (Mexico) – April 2018
- Note: Receptor limitations have been ignored by most TB studies
- Dickensian diseases are returning – rickets, gout, whooping cough, TB, etc. (low vitamin D)
- TB treatment by Vitamin D – some problems, except for Clinic C – June 2017
- Tuberculosis recovery speeded up by single 450,000 IU dose of vitamin D – RCT Jan 2017
- Note: Most TB studies have ignored loading doses
- Tuberculosis -100 percent cure rate with 10,000 IU of vitamin D daily – RCT 2006
Tuberculosis (TB) has troubled mankind for millennia, but current treatment strategies are long and complicated and the disease remains a major global health problem. The risk of Mycobacterium tuberculosis (Mtb) infection or progression of active TB disease is elevated in individuals with vitamin D deficiency.
High‐dose vitamin D was used to treat TB in the pre‐antibiotic era, and in vitro experimental data show that vitamin D supports innate immune responses that restrict growth of Mtb. Several randomised controlled trials have tested whether adjunctive vitamin D supplementation enhances the clinical and microbiological response to standard antimicrobial chemotherapy for pulmonary TB.
The effects have been modest at best, and attention is turning to the question of whether vitamin D supplementation might have a role in preventing acquisition or reactivation of latent Mtb infection. In this article, we describe the effects of vitamin D on host immune responses to Mtb in vitro and in vivo, and review the results of clinical trials in the field. We also reflect on the findings of clinical trials of vitamin D supplementation for the prevention of acute respiratory tract infections, and discuss how these findings might influence the design of future trials to evaluate the role of vitamin D in the prevention and treatment of TB.